Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-3512676 + gemcitabine + cisplatin
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
PF-3512676 + gemcitabine + cisplatin is a **combination regimen** investigated for the treatment of advanced non-small-cell lung cancer (NSCLC). PF-3512676 (also known as CpG 7909 or ProMune) is a synthetic oligodeoxynucleotide that acts as a Toll-like receptor 9 (TLR9) agonist, activating plasmacytoid dendritic cells and B lymphocytes, thereby stimulating innate and adaptive immune responses to enhance antitumor immunity. Gemcitabine is a nucleoside analog used as a cytotoxic chemotherapeutic agent, and cisplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and cell death. The rationale for this combination was to augment the presentation of tumor antigens generated by chemotherapy and enhance immune response via PF-3512676. Phase III trials demonstrated that adding PF-3512676 to gemcitabine/cisplatin did not improve clinical efficacy and increased toxicity; as a result, development of this combination was discontinued for NSCLC[1][4][5].
- Brand names
- ProMune
- Other names
- CpG 7909CpG7909CpG-7909
02
Targets
DNATLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on PF-3512676 + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-3512676 + gemcitabine + cisplatin.